Compare Bristol-Myers Squibb Co (BMY) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Howmet Aerospace Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while Howmet Aerospace Inc trades at $274.75 (market cap $110.74B). The key difference: Bristol-Myers Squibb Co and Howmet Aerospace Inc are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HWM | |
|---|---|---|
Market Cap | $116.30B | $110.74B |
Sector | Health | Industrials |
52-Week High | $62.37 | $283.23 |
52-Week Low | $42.60 | $171.00 |
Enterprise Value | $152.24B | $112.99B |
Dividend Yield | 4.42% | 0.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Howmet Aerospace (HWM) trades at $271.28, up 0.16% on the day, with a neutral technical signal but strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.22 exceeding expectations. Revenue growth and robust profit margins, including a 20.22% net income margin, support its premium valuation multiples. Recent news highlights strength in commercial aerospace demand as a key growth driver.
The outlook remains positive given analyst consensus with 84% buy ratings and a $317.63 price target, suggesting ~17% upside. However, elevated valuation ratios like a P/E of 64.22 pose risks if growth slows. Key catalysts include Q2 2026 results on August 6, 2026, while reliance on aerospace cycles and competitive pressures are monitoring points for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
